Document is current
Any future updates will be listed below
-
Authors
Abouelmagd, Moaz Elsayed https://orcid.org/0000-0002-0511-2429
Aldemerdash, Mohamed A.
Khatatbeh, Abdallah Ahmad https://orcid.org/0000-0001-8299-6945
Osman, Ahmed S.A https://orcid.org/0009-0002-2871-9925
Abbas, Abdallah
Allam, Salma https://orcid.org/0009-0005-2749-8982
AlEdani, Esraa M. https://orcid.org/0009-0005-0001-9830
Aldemerdash, Ahmed
Monteith, Teshamae S. https://orcid.org/0000-0001-8912-252X
-
Funding
Funding for this research was provided by:
Cairo University
- License Information
-
More Information
Article History
Received: 29 June 2025
Accepted: 11 December 2025
First Online: 2 February 2026
Declarations
:
: The authors declare no competing interests.
: Teshamae Monteith has the following disclosures over the past three years: clinical trial site principal investigator for studies sponsored by AbbVie, Eli Lilly, Ipsen, Merz and Rehaler, participation in advisory board/consultancy for AbbVie, Teva, e-Neura, Lundbeck, Novartis, Axsome, Therapeutics, Merz, Amneal, and Pfizer, an educational grant from Amgen and AbbVie, personal fees from Medscape, Massachusetts Medical Society, American Headache Society, American Academy of Neurology, Canadian Headache Society, Academic CME, AbbVie, Novartis, unpaid co-author for research funded by AbbVie, Pfizer/Biohaven, and Theranica. She has done editorial work for Cephalalgia and Continuum Audio and is on the editorial board for Neurology , American Migraine Foundation, New England Journal of Medicine Clnician, and Brain and Life Magazine . She has provided unpaid service on the board of directors for the International Headache Society (2021-2023) and currently sits on the executive board for the Florida Society of Neurology.
